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ABSTRACT 
 
Retinoblastoma is the most frequent malignant intraocular tumour of 
childhood, and in Africa it is the commonest and most important life 
threatening ocular neoplasm. In resource-rich countries such as the United 
States and Canada, survival rates for patients with retinoblastoma approach 
100%. This is in stark contrast to developing countries where survival rates 
may be less that 20%. Despite the vast majority of affected patients living in 
less developed countries, there is little attention and published literature on 
disease characteristics in these populations. 
OBJECTIVES: To characterise retinoblastoma in the South African population 
through a 20-year retrospective analysis of patient records at two tertiary 
academic hospitals in Johannesburg. 
DESIGN AND METHOD: Retrospective clinical case series analysis of 
medical records of patients with retinoblastoma presenting to Charlotte 
Maxeke Johannesburg Academic Hospital and Chris Hani Baragwanath 
Academic Hospital between 01 January 1992 and 31 December 2011. 
RESULTS: The total number of retinoblastoma cases identified was 282, with 
245 of these meeting the study inclusion criteria. Retinoblastoma comprised 
6.9% of total paediatric oncology presentations. 65.3% were unilateral, 34.3% 
bilateral and 0.4% trilateral. The overall male to female ratio was 1.08. Mean 
age at presentation overall was 32.6 months (median 28.0 months), for 
unilateral 39.4 months (median 33.0 months) and for bilateral 19.7 months 
(median 17.0 months). The mean delay to presentation overall was 7.0 
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months (median 4.0 months), for unilateral 8.5 months (median 5.0 months) 
and for bilateral 4.4 months (median 3.0 months). The most frequent 
presenting symptoms were leukocoria (37.1%) and proptosis (34.7%). 
Distribution of disease stage at presentation (using the International 
Retinoblastoma Staging System) was 1.6% with Stage 0, 24.1% with Stage I, 
27.8% Stage II, 16.3% Stage III and 25.3% Stage IV (data not available in 
4.9%). 26.5% of patients defaulted care. The five-year survival rate was 
57.7% in the overall study population, and according to disease stage at 
presentation: 95.3% - Stage I, 84.8% - Stage II, 49.7% - Stage III and 5.7% - 
Stage IV.  
CONCLUSION: The five-year survival rate for Stage I disease is similar to the 
overall five-year survival rates reported in the developed world. This suggests 
that treatment standards at the study hospitals are comparable with those of 
developed countries and that similar overall survival rates may be achieved if 
patients were to present as early. Delay to presentation, disease stage at 
presentation and defaulting care were identified as key factors contributing to 
the poor overall survival rate. This study provides information regarding 
patient demographics, social challenges in management, and patient 
outcomes in comparison to developed countries and to reports from other 
African populations. It also highlights the need for educational campaigns and 
screening initiatives to address poor survival outcomes as a result of late 
presentation and high rates of patients defaulting care. Finally, this report 
serves as a platform for comparison with future research in this area. 
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CHAPTER 1 
 
1.1 INTRODUCTION AND LITERATURE REVIEW 
Retinoblastoma is the most frequent malignant intraocular tumor of childhood, 
and in Africa it is the commonest and most important life threatening ocular 
neoplasm.1,2,3  
In Europe, North America and Australia, retinoblastomas account for 2 to 4% 
of total neoplasms in children, with similar relative frequencies in Asia, while in 
African populations retinoblastoma is reported to account for 10-15% of 
childhood cancers.4 
Epidemiological studies suggest an incidence of approximately 1 in 16,000 to 
18,000 births annually worldwide.5 
 
Retinoblastoma is a cancer with a genetic aetiology, and arises from 
mutations in both alleles of the Retinoblastoma gene (RB1). The disease may 
occur in a heritable (germline mutation) and non-heritable form (somatic 
mutation). In germline mutations the mutation is present in all cells of the body 
and is transmitted to the affected individual’s offspring. In somatic mutations, 
only the tissue of concern has the mutation, and there is no chance of 
transmitting the disease to offspring.3,6 The heritable form includes all cases 
of bilateral and familial retinoblastoma, as well as a few cases of unilateral 
tumour – a mutation in the RB1 gene is either inherited from an affected 
parent or arises spontaneously in one chromosome, and a spontaneous 
mutation occurs in the remaining copy of the gene which results in the 
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disease.3,6 While unilateral sporadic retinoblastoma is usually not heritable, 
approximately 15% of patients demonstrate a germline mutation.3,7 
Patients with a germline mutation are at increased risk of developing a 
neuroblastic intracranial malignancy, most frequently a pinealoblastoma, and 
this has been termed “trilateral” retinoblastoma – it occurs in approximately 
3% of all cases, and up to 10% of those with bilateral or familial 
retinoblastoma.3 
In poorly developed countries, as in the majority of sub-Saharan Africa, most 
patients with retinoblastoma succumb to advanced, disseminated disease, 
and familial retinoblastoma is uncommonly seen.1,2,8 In middle-income, 
developing countries, improved treatment has decreased mortality rates, 
resulting in a greater number of survivors with heritable RB1 mutations, and 
later, a corresponding increase in the proportion of familial retinoblastoma 
cases seen.8 In developed countries, up to 12% of retinoblastoma cases 
inherit a RB1 mutation from an affected parent.7,8  
 
The genetics of retinoblastoma do not lend preference to any particular sex, 
and the majority of studies find an equal incidence of the disease in males 
and females.9,11 There are, however, several authors that have reported a 
higher incidence in males.1,2,4,10,12  
 
Unilateral retinoblastoma is more common and accounts for approximately 
two-thirds of all cases in developed countries.3,7,9 It accounts for an even 
greater proportion of cases in poorly developed countries, most likely due to 
higher mortality rates in these populations.1,2,4,10  
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In developed countries the majority of retinoblastoma cases present before 
the age of five years. Bilateral retinoblastoma typically occurs at a younger 
age than unilateral disease.11,13 The mean age at presentation for both 
unilateral and bilateral retinoblastoma is higher in poorly developed countries, 
and is most probably due to delayed presentation.1,2,3  
 
Late presentation is invariably the cause for increased mortality rates in poorly 
developed countries and reports from African countries including the 
Democratic Republic of Congo, Nigeria, Tanzania, Mali, South Africa and 
Kenya demonstrate this.1,2,10,12,15,16,17,18 A South African study by Wainwright 
et al in 2011 reported that the average time delay between the onset of 
symptoms and diagnosis of retinoblastoma was 10.1 months.17 This is similar 
to other African studies, with delays generally in excess of 6 months, and up 
to 15 months being reported.1,2,15 Nyamori et al found that in Kenya, even 
patients with a family history of retinoblastoma had a delayed presentation.12 
Late presentation in developing countries is thought to be a result of poor 
awareness of retinoblastoma by both the public and healthcare professionals, 
difficulties accessing healthcare in remote areas, cultural beliefs, as well as 
regional differences in attitudes towards disease.2,3,8,19  
 
The presenting signs of retinoblastoma in the developed world are most 
commonly leukocoria (“white pupil”) or strabismus (squint).1,20 Other 
presenting signs include proptosis (protrusion of the globe), eyelid swelling, 
and signs of intraocular inflammation. Reports from sub-Saharan Africa 
suggest that leukocoria and proptosis, rather than strabismus, are the 
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commonest presentations of retinoblastoma in this population1,2,10,15,21 The 
difference in presentations is probably linked to delayed diagnosis, with 
patients presenting with advanced disease when globe displacement and 
extraocular spread has occurred.11 
 
Retinoblastoma without treatment is almost invariably fatal. Management of 
the disease is often complex and highly individualized. It is guided by several 
factors such as the threat of metastatic disease, risk for second cancers, 
systemic status, laterality of the disease, size and location of tumour(s), and 
estimated visual prognosis.3 Coordinated care is required between the tertiary 
eye care centre, paediatric oncologists, pathologists and interventional 
radiologists.5 Enucleation involves careful removal of the eye with a long 
section of the optic nerve to minimize any globe trauma and tumour spread 
into the orbit; it is the favoured approach for extensive retinoblastoma, 
especially if it is unilateral.7,20,22,23 Treatment modalities have evolved over 
recent decades, and available options in developed countries now include 
intravenous chemoreduction (carboplatin, etoposide, and vincristine), intra-
arterial chemotherapy, subconjunctival carboplatin, thermotherapy, 
cryotherapy, laser photocoagulation, plaque radiotherapy, external beam 
radiotherapy, and enucleation.3,20,23 Intravitreal chemotherapy has been 
trialed recently for recurrent vitreous seeding following failed therapies, with 
early reports suggesting that extraocular extension of the disease as a result 
of the injection is rare.20,24  Over the past decade, there has been a trend 
towards vision-preserving treatment, and many retinoblastoma patients with 
bilateral disease who would have undergone enucleation have been 
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controlled without removing the eye, and without any changes in the mortality 
rates.22 In the United States, enucleation rates for patients with unilateral 
retinoblastoma have also decreased.5,7,20,22 Authors caution that careful 
patient selection for eye-conserving treatment is mandatory, and reinforce that 
retinoblastoma treatment be aimed at child survival, followed by globe salvage 
and preservation of vision.5,7,20  
 
Several classifications of retinoblastoma have been developed as treatment 
strategies have evolved. The Reese-Ellsworth classification for retinoblastoma 
was developed in the 1960’s, and until recently was the primary classification 
system used for intraocular retinoblastoma.5,22 (Appendix B) It was developed 
to predict treatment success (globe salvage) following radiotherapy, which 
was a key treatment modality at the time. 5,22 As preferred treatment methods 
shifted away from radiotherapy in later years, a modified classification system, 
the International Classification of Retinoblastoma (ICRB), was proposed in 
2005. (Appendix C) The ICRB is replacing the Reese-Ellsworth classification 
in clinical practice as it is more in line with contemporary treatment strategies 
by better predicting treatment success (globe salvage and avoidance of 
radiotherapy) with chemoreduction and local treatments.3,5,22 Less developed 
countries frequently encounter retinoblastoma when extraocular spread has 
occurred. In this setting it is more practical to adopt a staging system that 
addresses extraocular extension of the disease and systemic involvement. 
Several staging systems for extraocular retinoblastoma have been proposed, 
however none has been universally and consistently applied.25,26 Following 
introduction of the newer ICRB classification for intraocular retinoblastoma, an 
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international consortium of ophthalmologists and paediatric oncologists 
reviewed existing staging systems for extraocular retinoblastoma. In 2006 
they proposed a new simplified staging system, the International 
Retinoblastoma Staging System (IRSS), with the aim of better predicting 
survival.25 (Appendix D) 
 
In resource-rich countries such as the United States and Canada, survival 
rates for patients with retinoblastoma approaches 100%.5,18 This is in stark 
contrast to poorly developed countries, where the majority of affected children 
live - survival rates in some of these populations may be less than 
20%.1,2,5,14,18,27,28 Despite more than 90% of affected patients living in poorly 
developed countries, there is little attention and published literature on 
disease characteristics in these populations.27 
 
1.2 RESEARCH AIM 
 
The aim of this research project was to characterize retinoblastoma in the 
South African population through a 20-year retrospective analysis of 
retinoblastoma patient records at two tertiary South African academic 
hospitals in Johannesburg. 
 
1.3 RESEARCH OBJECTIVES 
 
The study sought to describe retinoblastoma in the research population group 
in terms of:  
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A. Total number of retinoblastoma cases over the study period 
B. Retinoblastoma cases as a proportion of total paediatric oncology 
presentations over the study period 
i. Proportion of retinoblastoma to non-retinoblastoma 
paediatric oncology presentations for each successive five-
year period of the study 
C. Number of records meeting the inclusion and exclusion criteria 
D. Laterality 
i. Proportion of bilateral to unilateral retinoblastoma 
presentations for each successive five year period of the 
study 
E. Sex distribution 
F. Age at presentation 
i. Overall 
ii. By laterality 
iii. By family history 
G. Delay to presentation 
i. Overall 
ii. By laterality 
iii. By family history 
H. Presenting symptoms 
i. Commonest presenting symptom 
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ii. Patients with leukocoria as the presenting symptom as a 
proportion of the total number of patients in whom leukocoria 
was evident at presentation 
iii. Patients with strabismus as the presenting symptom as a 
proportion of the total number of patients in whom 
strabismus was evident at presentation 
I. Genetic testing 
J. Disease stage at presentation 
i. By delay to presentation 
ii. By family history 
iii. By laterality 
K. Treatment administered 
L. Proportion of patients defaulting care 
M. Survival 
i. Overall 
ii. By stage 
iii. By laterality 
iv. By family history 
v. By delay to presentation 
vi. By defaulting care 
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CHAPTER 2 
 
2.1 STUDY DESIGN 
A retrospective clinical case series analysis of patient medical records and 
histopathological reports of patients with retinoblastoma presenting to 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and Chris Hani 
Baragwanath Academic Hospital (CHBAH) between 01 January 1992 and 31 
December 2011. 
 
2.2 DATA COLLECTION 
This study was conducted subsequent to submission of a research protocol to 
the Human Research Ethics Committee (Medical), University of 
Witwatersrand. The proposed study received ethics approval from the 
committee and a clearance certificate was issued, Reference M120726. 
(Appendix A) 
Consent to review patient medical records was obtained from the Chief 
Executive Officer of CMJAH and from the Superintendent of CHBAH.  
Statistical records of the number of paediatric patients presenting with 
oncological diseases to the paediatric oncology departments at CMJAH and 
CHBAH were reviewed. The total number of paediatric patients diagnosed 
with any oncological disease over the duration of the study period for both 
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hospitals was tallied. This data was recorded for comparison with the total 
number of retinoblastoma presentations over the study period. 
Retinoblastoma patients presenting during the study period were identified 
through review of a departmental record of all patients presenting to the 
paediatric oncology departments at CMJAH and CHBAH. The patient name 
and medical record number were utilised to retrieve the medical records for 
these patients. 
 
2.2.1 INCLUSION CRITERIA 
Cases of retinoblastoma diagnosed on the basis of clinical, imaging or 
histological findings between 01 January 1992 and 31 December 2011 were 
included in the study. 
 
2.2.2 EXCLUSION CRITERIA 
There were two basic exclusion criteria in the study: 
• Cases in which the diagnosis of retinoblastoma was not certain were 
excluded. 
• Patient Medical Records with grossly inadequate record keeping were 
excluded. 
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2.2.3 DATA MANAGEMENT 
Patient medical records meeting the inclusion criteria were reviewed and 
relevant data extracted by the primary researcher and recorded in a 
spreadsheet using Microsoft Excel for Mac 2011. Strict confidentiality was 
maintained in this study with each patient being assigned a case number to 
ensure anonymity. Patient names, medical record numbers and any identifiers 
were available to the primary researcher alone. 
The following information was extracted from each patient medical record: 
a) Date of presentation 
The initial date of presentation to CMJAH or CHBAH was recorded. 
 
b) Delay to presentation 
The period of time, recorded in months, from the date that symptoms or 
signs related to the diagnosis of retinoblastoma were initially noticed to 
the date that medical attention was first sought at any public or private 
health care facility.  
Some patients were diagnosed with retinoblastoma in the absence of 
any signs or symptoms, following a screening examination for the 
disease prompted by a positive diagnosis in a sibling. In these 
instances the delay to presentation was recorded as zero months. 
Inadequate record keeping precluded determination of the delay to 
presentation in some cases. The data entered in these cases reflected 
that the information was unavailable. 
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c) Age at presentation 
The youngest age, recorded in months, at which the patient initially 
presented to any private or public health care facility to seek medical 
attention for symptoms or signs related to the subsequent diagnosis of 
retinoblastoma.  
 
d) Sex 
Recorded as either male or female. 
 
e) Presence of a family history of retinoblastoma 
A documented family history of retinoblastoma was recorded as “yes”, 
along with details of the relationship of the affected family member to 
the patient. A “no” entry signified the absence of a family history of 
retinoblastoma. 
The data entry “not available” was used in cases where no family 
history was recorded or in instances where it was not possible to obtain 
a family history from the patient or persons accompanying the patient. 
 
f) Laterality  
Laterality was recorded as being unilateral, bilateral or trilateral as 
determined at the final date of follow-up available for the patient. The 
diagnosis of retinoblastoma in a single eye was recorded as unilateral, 
involvement of both eyes was recorded as bilateral, and cases with 
both eyes involved in the presence of a neuroblastic intracranial 
malignancy were recorded as trilateral. 
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g) Presenting symptom or complaint 
The symptom or sign related to the diagnosis of retinoblastoma that 
prompted the patient or family of the patient to seek medical attention. 
Other signs or symptoms related to the diagnosis of retinoblastoma 
that were initially or concurrently noted, but that did not in themselves 
cause the patient or family of the patient to seek medical attention were 
excluded. 
The presenting symptom or complaint recorded for those patients 
diagnosed with retinoblastoma in the absence of any signs or 
symptoms, following a screening examination for a positive family 
history of the disease, was “screening due to family history”. 
The data entry “not available” was used for instances where record 
keeping was inadequate or the history was not available from the 
patient, family or guardians of the patient. 
 
h) Other symptoms and signs at time of presentation 
These comprised all signs and symptoms related to the diagnosis of 
retinoblastoma, other than the presenting symptom or complaint, noted 
by either the patient, family, guardians or health care professionals 
prior to or at the time of presentation.  
The data entry “not available” reflected instances where record keeping 
was inadequate or the relevant history was unavailable from the 
patient, family or guardians of the patient. 
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i) Retinoblastoma staging for each eye 
The International Retinoblastoma Staging System (Appendix D) was 
used to retrospectively stage the disease in each eye after reviewing 
the results of all histopathological, cytological and radiological 
investigations performed for the patient.  
Patient factors such as defaulting care or refusal of investigations and 
management precluded staging of the disease both retrospectively and 
at the time of presentation in some cases. In these instances the stage 
of the disease was recorded as being unavailable.  
The data entry “unavailable” was also used in cases where medical 
records did not reveal the stage of the disease and inadequate record-
keeping did not allow for retrospective staging either. 
The ICRB classification (Appendix C) was introduced late in the second 
half of the study period so that earlier records reflected the Reese-
Ellsworth classification, which was the current standard at the time. 
Insufficient detail of ophthalmological findings at the time of 
examination in records from the early study period did not allow for 
retrospective staging of the disease using the newer ICRB 
classification. Records from the later study period were generally of 
sufficient detail to allow for intraocular classification by either the 
Reese-Ellsworth or ICRB classification systems. For consistency and 
comparison purposes the Reese-Ellsworth classification was therefore 
used throughout this research report. 
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j) Treatment administered for each eye 
The use of the following treatment options were recorded for each eye: - Local therapy (laser therapy, cryotherapy or a combination of 
the two) - Brachytherapy (either ocular or orbital) - Intravitreal chemotherapy - Enucleation - Exenteration - Intravenous chemotherapy - Intra-arterial chemotherapy - Local radiotherapy (Deep X-ray Therapy, DXT) - Palliative therapy 
In patients with bilateral disease the use of intravenous chemotherapy 
as a treatment indicated for the stage of disease in one eye was also 
recorded as a treatment option utilized in the second eye regardless of 
whether chemotherapy was indicated for the stage of disease in the 
second eye. 
Planned treatment was unable to be administered in some cases due 
to the patient defaulting or declining care. In these instances only the 
treatment administered was recorded.  
 
k) Genetic Testing 
Medical records were reviewed in each case for evidence of genetic 
investigations having been conducted on the patient.  
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In some cases it was not possible to determine whether or not genetic 
testing had been performed due to inadequate record keeping and an 
inability to trace early records on current laboratory systems. In these 
instances a data entry of “not available” was made. 
 
l) Incidences of the patient defaulting or refusing management 
Any incident of the patient refusing hospital treatment or defaulting care 
was positively noted if in the medical record it was also reflected to be 
a significant event in the management of the patient.  
A record was made of the incident regardless of whether it transpired 
prior to, during, or after treatment. 
 
m) Follow-up period  
The follow-up period was determined to consist of all visits subsequent 
to the completion of any planned treatment for disease, and was 
recorded in months from the date of last treatment administered to the 
date of last follow-up. 
 
n) Follow-up status  
The follow-up status was recorded as either complete or incomplete. 
Cases with a recorded follow-up period of any length were considered 
to be complete. In cases with advanced disease at presentation or with 
recurrence of disease at an advanced stage where no curative 
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treatment was planned, the follow-up status was recorded as 
“complete”. 
The follow-up status of patients who were treated with curative intent 
and then transferred to another hospital (other than CMJAH and 
CHBAH) was considered to be incomplete if there was no follow-up 
period at the study hospital for the patient subsequent to treatment. 
Patients who refused hospital treatment or defaulted treatment 
permanently were recorded as having an “incomplete” follow-up status 
regardless of the stage of disease at presentation or at time of default.  
Patients who defaulted treatment but returned at a later stage without 
subsequently defaulting treatment were considered to have a 
“complete” follow-up status.  
 
 
o) Patient survival status 
The patient’s survival status at the last recorded visit was described as 
either “dead” or “alive”.  
Where the stage of the disease was so advanced that no curative 
treatment was planned, the status was recorded as “dead”. 
Patients who refused hospital treatment or defaulted treatment 
permanently were recorded as having “undetermined” survival status. 
The survival status was recorded as “undetermined” for those patients 
transferred to another hospital (other than CMJAH or CHBAH). 
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2.3 DATA ANALYSIS 
All data analysis was carried out by the primary researcher using Stata 12 
software.29  
The 5% significance level was used throughout (all tests or parameters with a 
p-value below 0.05 were significant). 
Specific statistical methods and tests utilised are discussed under the relevant 
sections of the results chapter (chapter 3). 
 
2.4 STAFF AND ADMINISTRATION 
This study was conducted by Dr Saadiah Goolam (Ophthalmology registrar) 
and supervised by Dr Nicky Welsh (Ophthalmology consultant). The primary 
site of this study was the Paediatric Oncology department at CMJAH and 
CHBAH. 
 
2.5 ETHICAL CONSIDERATIONS 
This study was conducted subsequent to approval of a research proposal 
submitted to the Human Research Ethics Committee, University of 
Witwatersrand. An Ethics clearance certificate (Reference M120726) was 
obtained. (Appendix A) All patient names, medical record numbers and 
identifiers were kept confidential. 
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CHAPTER 3 
 
3.1 TOTAL NUMBER OF RETINOBLASTOMA CASES 
The total number of retinoblastoma presentations recorded over the 20-year 
study period was 282. A total of 221 presentations (78%) was recorded at 
CHBAH, and a total of 61 presentations (22%) was recorded at CMJAH.  
 
3.2 RETINOBLASTOMA AS A PROPORTION OF TOTAL PAEDIATRIC 
ONCOLOGY PRESENTATIONS 
The total number of paediatric oncology presentations over the study period 
was 4108 (2010 at CMJAH and 2098 at CHBAH), with confirmed 
retinoblastoma comprising 282 (6.9%) of these.  
The number of paediatric oncology and retinoblastoma presentations for each 
successive five-year period was determined. The proportion of retinoblastoma 
to non-retinoblastoma paediatric oncology presentations for each of the 
successive five-year periods is shown in Figure 1.  
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Figure 1. The proportion of retinoblastoma to non-retinoblastoma paediatric 
oncology presentations per successive five-year period of the study. 
There was no statistically significant relationship between the proportions of 
retinoblastoma to non-retinoblastoma paediatric oncology presentations over 
the successive five-year periods of the study (X2 test, p=0.36). 
 
3.3 RETINOBLASTOMA CASES MEETING CRITERIA 
A total of 282 cases meeting the inclusion criteria were identified. Of these, 
245 cases (86.9%) met the inclusion and exclusion criteria - 37 records were 
excluded from the study due to inadequate or unavailable medical records. No 
cases were excluded on the basis of an incorrect or uncertain diagnosis of 
retinoblastoma. Of the 245 cases, 193 (78.8%) were from CHBAH and 52 
(21.2%) were from CMJAH.  
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3.4 LATERALITY 
Table 1. Laterality of disease in the study population 
LATERALITY 
 Number of cases Percentage 
Unilateral 160 65.3% 
Bilateral 84 34.3% 
Trilateral 1 0.4% 
Total 245 100% 
 
The proportion of hereditary (bilateral and trilateral) retinoblastoma to 
unilateral retinoblastoma for each successive five-year period of the study is 
shown in Figure 2. 
 
Figure 2. The proportion of hereditary (bilateral and trilateral) retinoblastoma 
to unilateral retinoblastoma per successive five-year period of the study. 
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There was no statistically significant relationship between the proportions of 
hereditary to unilateral retinoblastoma presentations over successive five-year 
periods of the study (X2 test, p=0.49). 
 
3.5 SEX DISTRIBUTION 
The distribution of male and female patients in the overall study population as 
well as in the unilateral and bilateral groups is presented in Table 2. 
Table 2. Sex distribution in the study population 
* Includes trilateral retinoblastoma 
The overall ratio of male to female in the study was 1.08, and 1.30 in the 
bilateral group. There was no statistically significant association between sex 
and laterality (X2 test, p=0.29). 
 
 
 
 
SEX 
 Overall Bilateral* Unilateral 
Male 127   (51.8%) 48   (56.5%) 81    (50.6%) 
Female 118   (48.2%) 37   (43.5%) 79    (49.4%) 
Total 245 85 160 
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3.6 AGE AT PRESENTATION 
The univariate statistics for the continuous variable “Age at Presentation” 
(overall and grouped by laterality and family history) are presented in Table 3.   
Figure 3, Figure 4 and Figure 5 show box and whisker plots for Age at 
presentation overall, and by laterality and family history respectively. 
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Table 3. Univariate statistics for age at presentation in the overall study group, 
and grouped by laterality and family history. (Significant results are marked in 
red) 
AGE	AT	PRESENTATION*	
	 OVERALL	 LATERALITY	 FAMILY	HISTORY	
UNILATERAL	 BILATERAL**	 YES	 NO	
n	 245	 160	 85	 17	 219	
Mean	 32.6	 39.4	 19.7	 20.3	 33.4	
Median	 28.0	 33.0	 17.0	 21.0	 28.0	
Minimum	 0.5	 1.5	 0.5	 0.5	 1.5	
Maximum	 238.0	 238.0	 70.0	 47.0	 238.0	
Lower	
Quartile	
17.0	 24.0	 8.0	 8.0	 17.0	
Upper	
Quartile	
40.0	 47.5	 29.0	 29.0	 40.0	
Std.	
Deviation	
26.8	 29.3	 14.2	 14.7	 27.5	
Skewness	 3.01	 2.98	 0.95	 0.39	 3.04	
Kurtosis	 16.27	 14.55	 1.15	 -0.86	 15.99	
z(skew)	 19.25	 15.41	 3.59	 0.65	 18.34	
z(kurt)	 51.99	 37.56	 2.16	 -0.72	 48.29	
p-value	for	
Shapiro-Wilk	
test	for	
normality***	
<0.0001	 <0.0001	 <0.0001	 0.35	 <0.0001	
	 	 	
p-value	for	Wilcoxon	Rank	
Sum	test	for	differences	
between	groups	
<0.0001	 0.026	
* Age at presentation in months 
** Includes trilateral retinoblastoma 
*** Tested at the 1% significance level 
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3.6.1 Overall 
 
Figure 3. Box and whisker plot of age at presentation in overall population. 
Tests for normality and skewness (Table 3) show that the variable is positively 
skewed and exhibits significant non-normality (p<0001).  
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3.6.2 Laterality 
 
Figure 4. Box and whisker plot of age at presentation by laterality. 
Tests for normality and skewness (Table 3) show that the variables are 
positively skewed and exhibit significant non-normality (p<0.0001). Therefore 
the Wilcoxon Rank Sum test (the non-parametric equivalent of the 
independent samples t-test) was used for between-group comparisons since 
the assumptions of the t-test were not met. There was a statistically significant 
difference between the laterality groups (p<0.0001). Patients with hereditary 
retinoblastoma (bilateral and trilateral) had a lower median age at 
presentation (17 months) than those with unilateral retinoblastoma (median 
age at presentation 33 months). 
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3.6.3 Family History 
 
Figure 5. Box and whisker plot of age at presentation by family history. (“Y” 
indicates a positive family history; “N” indicates no family history of 
retinoblastoma). 
Tests for normality and skewness (Table 3) show that the variable age by 
presentation is positively skewed and exhibits significant non-normality in the 
group of patients without any family history of the disease (p<0.0001). The 
Wilcoxon Rank Sum test was thus used for between-group comparison. There 
was a statistically significant difference between the two groups (p=0.026). 
Patients with a positive family history presented earlier (median age 21 
months) than those without a family history of the disease (median age 28 
months). 
 
	 28	
3.7 DELAY TO PRESENTATION 
The univariate statistics for the continuous variable “Delay to Presentation” 
(overall and grouped by laterality and family history) are presented in Table 4.   
Figure 6, Figure 7 and Figure 8 show box and whisker plots for Delay to 
presentation overall, and by laterality and family history respectively. 
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Table 4. Univariate statistics for delay to presentation in the overall study 
group, and grouped by laterality and family history. (Significant results are 
marked in red) 
DELAY	TO	PRESENTATION*	
	 OVERALL	 LATERALITY	 FAMILY	HISTORY	
UNILATERAL	 BILATERAL**	 YES	 NO	
n	 231	 148	 83	 16	 213	
Mean	 7.0	 8.5	 4.4	 4.0	 7.2	
Median	 4.0	 5.0	 3.0	 2.0	 4.0	
Minimum	 0.0	 0.0	 0.0	 0.0	 0.0	
Maximum	 72.0	 72.0	 24.0	 24.0	 72.0	
Lower	
Quartile	
1.0	 2.0	 1.0	 0.0	 2.0	
Upper	
Quartile	
10.0	 12.0	 6.0	 4.0	 10.0	
Std.	
Deviation	
8.7	 10.0	 5.0	 6.3	 8.8	
Skewness	 2.92	 2.62	 1.96	 2.44	 2.97	
Kurtosis	 14.20	 11.13	 4.33	 6.49	 14.61	
z(skew)	 18.11	 12.99	 7.29	 3.99	 17.72	
z(kurt)	 44.06	 27.65	 8.05	 5.30	 43.53	
p-value	for	
Shapiro-Wilk	
test	for	
normality***	
<0.0001	 <0.0001	 <0.0001	 <0.0001	 <0.0001	
	 	 	
p-value	for	Wilcoxon	Rank	
Sum	test	for	differences	
between	groups	
<0.0001	 0.021	
* Delay to presentation in months 
** Includes trilateral retinoblastoma 
*** Tested at the 1% significance level 
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3.7.1 Overall 
 
Figure 6. Box and whisker plot of delay to presentation in overall population. 
Tests for normality and skewness (Table 4) show that the variable is positively 
skewed and exhibits significant non-normality (p<0001).  
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3.7.2 Laterality 
 
Figure 7. Box and whisker plot of delay to presentation by laterality. 
Tests for normality and skewness (Table 4) show that the variables are 
positively skewed and exhibit significant non-normality (p<0.0001). Therefore 
the Wilcoxon Rank Sum test was therefore used for between-group 
comparisons. There was a statistically significant difference between the 
groups (p<0.0001). Patients with hereditary retinoblastoma (bilateral and 
trilateral) had a shorter median delay to presentation (3 months) than those 
with unilateral retinoblastoma (median delay to presentation 5 months). 
 
 
 
	 32	
3.7.3 Family History 
 
Figure 8. Box and whisker plot of delay to presentation by family history. (“Y” 
indicates a positive family history; “N” indicates no family history of 
retinoblastoma). 
Tests for normality and skewness (Table 4) show that the variable delay to 
presentation is positively skewed and exhibits significant non-normality in the 
group of patients without any family history of the disease (p<0.0001). The 
Wilcoxon Rank Sum test was thus used for between-group comparison. There 
was a statistically significant difference between the two groups (p=0.021). 
Patients with a positive family history had a shorter delay to presentation  
(median delay 2.0 months) than those without a family history of the disease 
(median age 4.0 months). 
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3.8 PRESENTING SYMPTOMS 
3.8.1 Frequency of Presenting Symptoms 
Data regarding Presenting Symptoms or complaint was unavailable in four 
cases. There were no symptoms reported in four cases where the diagnosis 
of retinoblastoma was made following screening for a positive family history of 
the disease. Figure 9 illustrates the relative proportion of each presenting 
symptom as a percentage. The most common presenting symptoms were 
leukocoria (37.1%) and proptosis (34.7%). 
 
Figure 9. Proportion of each presenting symptom represented as a 
percentage of total presenting symptoms. 
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3.8.2 Leukocoria 
Leukocoria was present in 186 patients, and was the presenting symptom or 
complaint in 91 (48.9%) of these patients. Figure 10 illustrates the presenting 
symptom or complaint in patients with leukocoria evident at presentation.  
 
Figure 10. Presenting complaint in patients with leukocoria (186 patients). 
 
3.8.3 Strabismus 
Strabismus was present in 25 patients, and was the presenting symptom in 13 
(52%) of these patients. Figure 11 illustrates the presenting symptom or 
complaint in patients with strabismus evident at presentation. 
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Figure 11.  Presenting complaint in patients with strabismus (25 patients). 
 
3.9 GENETIC TESTING 
Screening for genetic abnormalities was performed in 162 patients (66.1% of 
patients). It was not possible to determine if screening investigations had 
been performed in 3 cases (1.2%).  
 
3.10 DISEASE STAGE 
All results are for data pertaining to the stage of disease in the eye with the 
presenting complaint (i.e. only the first (presenting) eye in patients with 
bilateral retinoblastoma).  Data regarding stage of disease in the eye with the 
presenting complaint were available in 233 patients, and the results are 
presented in Table 5. 
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Table 5. Summary of the frequency of each stage of disease (International 
Retinoblastoma Staging System) at presentation for eyes with the presenting 
complaint only. 
IRSS	*	 Number	of	cases	 Percentage	
O	 4	 1.6%	
I	 59	 24.1%	
II	 68	 27.8%	
III	 40	 16.3%	
IV	 62	 25.3%	
Not	Available	 12	 4.9%	
* International Retinoblastoma Staging System  
 
Further analysis was carried out to determine the relationship, if any, between 
stage of disease and each of the variables Delay to Presentation, Family 
History and Laterality.  
 
3.10.1 Stage and Delay to presentation 
Delay to presentation was categorised as either A (delay ≤ 6 months) or B 
(delay > 6 months). Patients with missing data for either delay or stage of 
disease at presentation were excluded from this analysis.  
There was a significant association between Stage and Delay (X2 test, p < 
0.001). Patients with Stage 0 disease were then excluded due to the very 
small number of patients (n = 4), and all of these patients having delay A (≤ 6 
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months). The chi-square test was repeated and this again demonstrated a 
significant, moderate association between Stage and Delay (p < 0.001, 
Cramer’s V = 0.31).  
As shown in Figure 12, a longer delay to presentation (Delay B) was 
associated with more advanced disease stage (Stage III and IV).  
 
Figure 12.  Patients with Delay A (≤ 6 months) and B (> 6 months) as a 
percentage within each group of Disease Stage.  
 
Multinomial Logistic Regression analysis was performed using Disease Stage 
as the dependent variable (with Stage I as the reference category) and Delay 
as the independent variable (with Delay A as the reference category) (Table 
6). 
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Table 6. Summary of Multinomial Regression analysis and Likelihood Type 3 
test for Disease Stage with Delay to Presentation as the independent variable. 
(Significant results are marked in red.)  
MULTIINOMIAL REGRESSION ANALYSIS SUMMARY: DELAY 
Effect Level of 
Indepen
dent 
variable 
Disease 
Stage 
Estimate 
	 
Standard 
Error 
Wald 
Stat. 
Lower CL 
95,00% 
Upper CL 
95,00% 
p 
	 
Intercept 
1 
	 2 0.132 0.213 0.382 -0.286 0.549 0.537 
Delay B 2 -0.063 0.213 0.086 -0.480 0.355 0.769 
Intercept 
2 
	 3 -0.267 0.227 1.384 -0.711 0.178 0.239 
Delay B 3 0.763 0.227 11.339 0.319 1.207 0.001 
Intercept 
3 
	 4 0.122 0.205 0.351 -0.281 0.524 0.553 
Delay B 4 0.458 0.205 4.981 0.056 0.861 0.026 
 
 Degrees of 
Freedom 
Log-Likelihood Chi-Square p 
DELAY 3 -294.1 20.0 0.00017 
 
 Delay was found to be significantly associated with Stage of Disease (p = 
0.00017). Patients with Stage III and IV disease were less likely to have Delay 
A (≤ 6 months) compared to Delay B (> 6 months), compared to patients with 
Stage I disease. 
 
3.10.2 Stage and Family History 
Patients with missing data for either family history or stage of disease at 
presentation were excluded from this analysis. 
Fisher’s exact test was used to test for an association between Disease Stage 
and Family history since the assumptions of the chi-square test were not met 
in this case. A significant association was found between the two variables (p 
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< 0.001).  The test was then repeated with Stage 0 disease excluded (due to 
the very small number of patients overall with Stage 0 disease (n = 4), with all 
four of the patients with Stage 0 disease having a positive family history).  
There was no significant relationship between Disease Stage (I – IV) and 
Family history (p = 0.56). 
Delay was already shown to be significantly associated with Stage, and 
therefore Multinomial Regression analysis was performed to determine the 
relationship between Stage and Family history whilst controlling for Delay. 
Stage 0 was excluded due to the small number of patients (n = 4), and lack of 
data for Delay B or negative family history in this group. The reference 
categories were Disease Stage I, Delay A and negative Family history. With 
Family history as the only independent variable analysed, there was no 
significant effect of family history on Disease Stage (p = 0.48). With both 
Delay and Family history as independent variables, Delay was found to have 
a significant effect on Stage (p = 0.00049) while Family history did not (p = 
0.72) (Table 7). 
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Table 7. Summary of Multinomial Regression analysis for Disease Stage with 
Family history as the independent variable; and Likelihood Type 3 test for 
Delay and Family history as the independent variables. (Significant results are 
marked in red.) 
MULTIINOMIAL REGRESSION ANALYSIS SUMMARY: FAMILY 
HISTORY 
Effect Level of 
Indepen
dent 
variable 
Disease 
Stage 
Estimate 
	 
Standard 
Error 
Wald 
Stat. 
Lower 
CL 
95,00% 
Upper 
CL 
95,00% 
p 
	 
Intercept 
1 		 2 0.487 0.445 1.195 -0.386 1.359 0.274 
Delay B 2 -0.057 0.213 0.072 -0.476 0.361 0.789 
Family 
History Y	 2 0.394 0.429 0.846 -0.446 1.235 0.358 
Intercept 
2 	 3 -0.390 0.637 0.375 -1.638 0.858 0.540 
Delay B	 3 0.717 0.229 9.805 0.268 1.166 0.002 
Family 
History Y 3 -0.083 0.632 0.017 -1.322 1.156 0.895 
Intercept 
3 	 4 0.350 0.479 0.535 -0.589 1.289 0.465 
Delay B 4 0.461 0.206 5.034 0.058 0.864 0.025 
Family 
History Y 4 0.250 0.472 0.281 -0.675 1.175 0.596 
 
 Degrees of 
Freedom 
Log-Likelihood Chi-Square p 
DELAY 3 -289.8 17.8 0.00049 
FAMILY 
HISTORY 
3 -299.8 2.5 0.48 
 
Family history was thus found to have no significant association with Disease 
Stage (I –IV) overall and when controlling for Delay. 
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3.10.3 Stage and Laterality 
No patients were excluded as there was no missing information regarding 
laterality of the disease.  
There was a significant, weak relationship between Laterality and Disease 
Stage (X2 test, p = 0.006, Cramer’s V = 0.25). The test was repeated with 
Stage 0 excluded due to the small number of patients in this group (n = 4), 
and all of them having bilateral disease. There was a no significant 
relationship between Disease Stage (I –IV) and Laterality (X2 test, p = 0.083). 
Delay was already shown to be significantly associated with Stage, and 
therefore Multinomial Regression analysis was performed to determine the 
relationship between Stage and Laterality whilst controlling for Delay. Stage 0 
was excluded due to the small number of patients (n = 4), and lack of data for 
Delay B or Unilateral disease in this group. The reference categories were 
Disease Stage I, Delay A and Unilateral disease. With Laterality as the only 
independent variable analysed, there was no significant effect of laterality on 
Disease Stage (p = 0.083). Multinomial Regression analysis was repeated 
with both Delay and Laterality as independent variables. Delay was found to 
have a significant effect on Stage (p = 0.0006) while Laterality did not (p = 
0.52) (Table 8).  
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Table 8. Summary of Multinomial Regression analysis for Disease Stage with 
Laterality as the independent variable; and Likelihood Type 3 test for Delay 
and Laterality as the independent variables. (Significant results are marked in 
red.) 
MULTIINOMIAL REGRESSION ANALYSIS SUMMARY: LATERALITY 
Effect Level of 
Indepe
ndent 
variable 
Disease 
Stage 
Estimate 
	 
Standard 
Error 
Wald 
Stat. 
Lower CL 
95,00% 
Upper CL 
95,00% 
p 
	 
Intercept 
1 		 2 0.200 0.223 0.801 -0.238 0.637 0.371 
Delay B	 2 -0.021 0.217 0.009 -0.446 0.404 0.923 
Laterality Bilat	 2 0.208 0.191 1.191 -0.166 0.582 0.275 
Intercept 
2 		 3 -0.312 0.254 1.509 -0.810 0.186 0.219 
Delay B 3 0.745 0.231 10.450 0.293 1.197 0.001 
Laterality Bilat	 3 -0.100 0.247 0.165 -0.585 0.384 0.685 
Intercept 
3 	 4 0.129 0.222 0.339 -0.306 0.565 0.560 
Delay B	 4 0.462 0.209 4.880 0.052 0.871 0.027 
Laterality Bilat 4 0.019 0.209 0.008 -0.390 0.429 0.927 
 
 Degrees of 
Freedom 
Log-Likelihood Chi-Square p 
DELAY 3 -291.7 17.3 0.00061 
LATERALITY 3 -284.1 2.2 0.52 
 
Laterality was thus found to have no significant association with Disease 
Stage (I –IV) overall and when controlling for Delay. 
 
3.11 TREATMENT ADMINISTERED 
Patients who defaulted care prior to planned treatment were excluded from 
the analysis of treatment for stage of disease. 311 eyes in total were included 
for analysis. 
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3.11.1 Stage 0 
38 eyes were treated for Stage 0 disease (IRSS, subject to further staging 
using intraocular classification system). All Stage 0 disease occurred in 
patients with bilateral retinoblastoma. The vast majority of these were 
recorded as having been treated with intravenous chemotherapy which was 
indicated as a treatment for the stage of disease in the first, presenting eye 
(stage of disease was more advanced than the second eye with Stage 0 
disease).  
Small tumours (Group I and Group II, Reese-Ellsworth Classification, n = 34) 
were treated predominantly with local therapy (laser photocoagulation and/or 
cryotherapy) (94.1%), and a smaller proportion received brachytherapy 
(26.5%) in addition to this. One patient in this group was treated with 
Intravitreal chemotherapy as well as Intra-arterial chemotherapy. 
No patients with Group III or IV disease (Reese-Ellsworth Classification) were 
treated (other than with enucleation). 
Four patients with Group V disease were treated with a combination of local 
therapy (laser photocoagulation and/or cryotherapy) and brachytherapy. One 
patient received intravitreal chemotherapy in addition to local therapy and 
brachytherapy. 
3.11.2 Stage I 
81 eyes were treated for Stage I disease. All 81 eyes underwent enucleation, 
4.9% received brachytherapy, 7.4% received DXT and 59.3% received 
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intravenous chemotherapy. In 37.5% of the patients that received intravenous 
chemotherapy, the treatment was an indication for the stage of disease in the 
first eye and was also reflected as a treatment for Stage I disease in the 
second eye. 
3.11.3 Stage II 
74 eyes were treated for Stage II disease. All 74 eyes were enucleated, 
90.5% were treated with intravenous chemotherapy, 46.0% received DXT and 
2.7% were treated with Brachytherapy prior to enucleation. 
3.11.4 Stage III 
40 eyes were treated for Stage III disease. 85% of eyes were enucleated and 
15% were exenterated. All patients received intravenous chemotherapy and 
87.5% received DXT. 
3.11.5 Stage IV 
78 eyes were treated for Stage IV disease. Treatment in this group was 
largely palliative. 16.7% of eyes were enucleated, 1.3% were exenterated, 
19.2% received chemotherapy, 15.3% received DXT and 79.5% received 
palliative treatment alone. 
 
3.12 PROPORTION OF PATIENTS DEFAULTING CARE 
65 patients (26.5%) were identified as having defaulted care. These consisted 
of patients who refused hospital treatment altogether as well as those who 
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defaulted during treatment (if this was also noted in the medical record to be a 
significant event in the patient’s management). 
 
3.13 SURVIVAL 
Patients that were transferred to another hospital prior to follow-up as well as 
patients that defaulted care before any treatment was initiated were excluded 
from this analysis.  
Kaplan-Meier survival curves were determined for the overall study 
population, as well as for Disease Stage, Laterality, Family History, Delay and 
Defaulting care. The Kaplan-Meier curves are presented under the 
corresponding sections that follow. 
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3.13.1 Overall Survival 
 
Figure 13. Kaplan-Meier survival curve for the overall study group 
There was a 57.7% five-year survival rate in the overall study population. 
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3.13.2 Stage 
 
Figure 14. Kaplan-Meier survival curves for stage of disease at presentation 
The five-year survival rates for stage of disease are presented in Table 9. 
Table 9. Five-year survival estimates for stage of disease at presentation 
STAGE OF DISEASE FIVE-YEAR SURVIVAL 
O 100% 
I 95.3% 
II 84.8% 
III 49.7% 
IV 5.7% 
The logrank test for differences in survival between the stages of disease was 
significant (p < 0.0001) with more advanced disease stage being associated 
with poorer survival rates.  
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3.13.3 Laterality 
 
Figure 15. Kaplan-Meier survival curves for laterality of disease (Bi – bilateral 
(includes trilateral disease), Uni – unilateral) 
The five-year survival was 55.7% in the bilateral group and 59.0% in the 
unilateral group. The logrank test for differences between the two groups was 
not significant (p = 0.62). 
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3.13.4 Family history 
 
Figure 16. Kaplan-Meier survival curves for Family history of retinoblastoma 
(N – no family history, Y – positive family history). 
The five-year survival was 56.5% in the group without a family history of 
retinoblastoma and 72.7% in the group with a positive family history for the 
disease. The logrank test for differences between the two groups was not 
significant (p = 0.19). 
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3.13.4 Delay to Presentation 
 
Figure 17. Kaplan-Meier survival curves for Delay to presentation (Delay A: ≤ 
6 months, Delay B: > 6 months). 
The five-year survival was 61.4% in the group with Delay A, and 54.1% in the 
group with Delay B. The logrank test for differences between the two groups 
was not significant (p = 0.23). 
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3.13.4 Defaulting Care 
 
Figure 18. Kaplan-Meier survival curves for Defaulting care (Y – patients 
defaulting care, N – no significant default). 
The five-year survival was 28.3% in the group that defaulted care, and 64.0% 
in the group without default. The logrank test for differences between the two 
groups was significant, with patients in the group that defaulted care having a 
poorer survival outcome (p = 0.0004). 
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CHAPTER 4 
 
DISCUSSION 
Retinoblastoma accounted for 6.9% of overall paediatric oncology 
presentations over the 20-year study period. This is higher than most 
developed countries (2% - 4%) but lower than the rates suggested in other 
developing countries in Africa (10% - 15%).4,10,28 There was no statistically 
significant relationship between the proportion of retinoblastoma to non-
retinoblastoma paediatric oncology presentations over successive five-year 
periods of the study (p=0.36), suggesting that there was no underlying trend 
in the proportion of retinoblastoma to non-retinoblastoma paediatric oncology 
presentations over the 20 years.  
A total of 282 cases of retinoblastoma was seen over the study period with the 
majority recorded at CHBAH (78%). Of the 282 patients with retinoblastoma, 
245 (86.9%) met both the inclusion and exclusion criteria with 37 patients 
being excluded due to inadequate or unavailable medical records. Lack of 
availability of complete medical records is a feature not uncommon in 
developing countries in Africa.2,14  
Unilateral retinoblastoma comprised approximately two-thirds of patients 
(65.3%), with hereditary (bilateral and trilateral) disease making up the 
remaining approximately one-third of patients (34.7%). This is consistent with 
the two-thirds unilateral and one-third bilateral distribution of disease reported 
in the developed world.3,7,30,31 There was no statistically significant 
relationship between the proportion of bilateral retinoblastoma to unilateral 
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retinoblastoma over successive five-year periods of the study (p=0.49). This 
suggests that there was no underlying trend in the proportion of bilateral to 
unilateral retinoblastoma over the 20-year period. The lack of any significant 
change in the proportion of bilateral to unilateral retinoblastoma also suggests 
a stable germline mutation in the study population.  
Screening for genetic abnormalities was performed in approximately two-
thirds of patients in the study population. This study did not analyse the 
results of any genetic testing performed due to difficulties in accessing results 
of investigations in the early study period as well as differences in the type of 
genetic tests performed over the study period.  
The genetics of retinoblastoma would anticipate an equal incidence of the 
disease in males and females. While several authors have suggested a male 
preponderance in retinoblastoma1,2,4,10, the results of this study are in keeping 
with the majority of reports that indicate no significant difference in the 
incidence of retinoblastoma in males and females.3,7,9 In addition, this study 
found no statistically significant association between sex and laterality 
(p=0.29).  
Unilateral disease is known to occur at an older age than bilateral disease, 
with the average age at presentation for both varying according to the 
developmental status of the population concerned. The mean age at 
presentation in the study population overall (32.6 months, median 28.0 
months), and for unilateral disease (39.4 months, median 33 months) and 
bilateral disease (19.7 months, median 17.0 months) is higher than the 
corresponding mean ages at presentation reported for each category in the 
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developed world.3,13,30 This study reports a statistically significant relationship 
between mean age at presentation and the variables laterality (p<0001) and 
family history (p=0.026). As expected, patients with bilateral disease and 
those with a positive family history of retinoblastoma presented earlier than 
their counterparts. This is consistent with findings on the mean age at 
presentation for unilateral and bilateral disease reported widely in the 
literature. 
Other African countries have also reported higher mean ages at presentation 
compared with the developed world, which, as in our study, is largely due to 
late presentation.1,2,12,14,21   The mean delay to presentation in the overall 
study group was 7.0 months (median 4.0 months). There was a statistically 
significant relationship between delay to presentation and the variables 
laterality (p<0.0001) and family history (p=0.021). Patients with bilateral 
disease and those with a positive family history for the disease had a shorter 
median delay to presentation than their counterparts.  
Late presentation is a feature in developing countries, with patients commonly 
presenting at a stage when extraocular spread of the disease has occurred. 
The commonest presenting symptoms in the study population were leukocoria 
(37.1%) and proptosis (34.7%), compared to the developed world where 
leukocoria and strabismus are the commonest presenting symptoms. This 
finding is similar to reports from other developing countries in Africa, and is 
the result of delayed presentation and diagnosis of the disease. 1,2,10,15,21 Of 
the total number of patients with leukocoria only 48.9% had leukocoria as their 
presenting complaint. Similarly, only 52% of patients with strabismus had this 
symptom as their presenting complaint. This suggests a lack of awareness in 
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the general population and probably primary health care workers as well (who 
are likely to see the children regularly for immunisation and developmental 
checks) as to the significance of leukocoria and strabismus as signs of a 
possible underlying neoplastic process.  
In keeping with the findings of significant delays to presentation and 
presenting symptoms indicative of advanced disease stage, the vast majority 
of patients presented at a stage where globe salvage was not possible. 
Intraocular Classification systems were not helpful in this setting, and the 
International Retinoblastoma Staging System was used for staging of the 
disease. Patients frequently presented with extraocular retinoblastoma, with 
27.8% presenting at Stage II, 16.3% at Stage III and 25.3% at Stage IV  
(Table 5). Only four (1.6%) patients were diagnosed at Stage 0 (where 
treatment did not necessitate enucleation), and all four of these patients were 
diagnosed with the disease subsequent to a screening examination prompted 
by the diagnosis of retinoblastoma in a sibling.  
Delay to presentation was found to be significantly, and independently 
associated with Disease Stage at presentation (p = 0.00017), with a longer 
delay to presentation (> 6 months) associated with more advanced disease 
stage (Stage III and Stage IV). Family History and Laterality were not 
significantly associated with Disease Stage at presentation. 
Late presentation with advanced disease stage in the presenting eye implied 
that largely only the second eye diagnosed in bilateral retinoblastoma cases 
was subject to treatment for Stage 0 disease. Newer treatment modalities 
such as intravitreal and intra-arterial chemotherapy more commonly used in 
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the developed world have not had much opportunity for use in this study. 
However at the close of the study period it is evident that these newer 
treatment modalities are being included in the treatment options available to 
select patients presenting earlier in the stage of the disease. Patients with 
Stage I disease were treated almost entirely with enucleation alone. Stage II 
disease was treated largely with enucleation coupled with intravenous 
chemotherapy, and this was supplemented by DXT in close to half of the 
cases. Stage III disease was treated predominantly with either enucleation or 
exenteration (in a smaller proportion of patients), intravenous chemotherapy 
and DXT. Stage IV disease received palliative treatment alone in the majority 
of cases.  
Advanced disease stage at presentation is accompanied by poor survival 
outcomes. This study reports a 57.7% five-year survival rate in the overall 
study population. Disease stage at presentation, as expected, was shown to 
be significantly associated with survival rates (p < 0.0001), with more 
advanced disease stages having poorer survival outcomes (Table 9). The 
five-year survival rate for Stage 0 is based on analysis of the only four 
patients with Stage 0 disease at presentation, and is therefore not likely to be 
a true representation of survival rates for this Stage of disease in the general 
population. The five-year survival rate for Stage I disease was 95.3% which is 
close to the overall five-year survival rates reported in the developed 
world.3,18,27 This suggests that overall survival rates may approach that of the 
developed world if patients were to present as early with minimal delay in 
accessing treatment. Stage II disease was associated with an 84.8% five-year 
survival rate, Stage III with 49.7% and Stage IV with 5.7%. Other than disease 
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stage at presentation, only defaulting care was found to be significantly 
associated with survival outcomes (p = 0.0004). Patients who defaulted care 
had a 28.3% five-year survival rate compared with 64.0% for patients without 
default. Delay to presentation was not found to be significantly associated with 
survival outcomes, however it is significantly and independently associated 
with disease stage at presentation. Laterality and family history were not 
significantly associated with survival outcomes.  
 
CONCLUSION 
This study provides information regarding patient demographics, social 
challenges in management, and patient outcomes in comparison to developed 
countries and to reports from other African populations. Like many reports 
from Africa, this study reflects the particular difficulties with late presentation 
and high rates of patients defaulting or refusing hospital treatment. The 
treatment practices employed in this setting probably have little influence on 
survival outcomes compared with advanced disease stage at presentation 
and defaulting care. Educational campaigns and screening programs aimed at 
increasing awareness and allowing for earlier detection of disease as well as 
decreasing rates of default are imperative in addressing the poor survival 
outcomes in our population. 
This study provides us with the necessary information to accompany and 
support proposals for primary health care awareness programs, patient 
education initiatives, state hospital resource allocation planning and finally, 
this study serves as a platform for comparison with future research in this 
area. 
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